<DOC>
	<DOCNO>NCT02376582</DOCNO>
	<brief_summary>The primary objective propose phase I trial evaluate safety tolerability DNA-HIV-PT123 AIDSVAX®B/E combination regimen . Though DNA-HIV-PT123 AIDSVAX®B/E combination two vaccine evaluate human show safe well tolerate , first time combination regimen evaluate HIV-1 uninfected African population without S. mansoni . The secondary objective trial evaluate effect S. mansoni infection immunogenicity combination DNA-HIV-PT123 AIDSVAX® B/E vaccine regimen . Successful vaccination virus require efficient Th1 response . There evidence helminth infection skew host immune system human animal T-helper type 2 ( Th2 ) induce immunosuppression . Therefore , potential helminth infect population may generate desire immune response vaccine design drive Th1-type cytotoxic T-cell response . Furthermore , influence helminth infection development protective antibody response remain unclear . Limited data animal model suggest worm infection reduce efficacy vaccine . The propose vaccine trial generate safety , tolerability immunogenicity data vaccination regimen simultaneous administration candidate HIV DNA vaccine ( DNA-HIV-PT123 ) gp120 protein vaccine ( AIDSVAX®B/E ) . This first HIV vaccine trial prospectively evaluate impact S. mansoni infection safety immune response HIV vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS</brief_title>
	<detailed_description />
	<criteria>1 . HIV1 uninfected adult age 1845 year , confirm medical history , physical exam , laboratory test screen 2 . In 50 % study volunteer , positive S. mansoni infection negative helminth infection . 3 . In 50 % study volunteer , negative S. mansoni helminth infection 4 . Willing forgo treatment praziquantel completion week 26 visit trial . 5 . Able willing provide write informed consent prior screen 6 . Aged 18 45 year day first vaccination 7 . Able willing complete screening ( 1 month ) available plan followup period ( 9months ) 8 . Willing undergo HIV testing , risk reduction counselling , receive HIV test result commit maintain low risk behaviour trial duration 9 . If female childbearing potential ( menopausal sterilise ) , willing use nonbarrier contraceptive method screen end study . Acceptable contraceptive method include hormonal contraceptive ( injection , transdermal patch , implant ) intrauterine device ( IUD ) . 10 . Willing provide blood , urine stool sample laboratory examination 1 . HIV1 infection 2 . Infection helminths 3 . Symptomatic asymptomatic malaria infection ( presence malaria parasites thick blood smear ) 4 . Treatment praziquantel past 3 month 5 . S. mansoni egg count &gt; 2000 egg per gram stool 6 . Clinically significant acute chronic illness time randomization . 7 . Any clinically relevant abnormality history examination 8 . Use immunosuppressive medication ( inhaled topical immunosuppressant ) 9 . Receipt immunoglobulin within past 60 day 10 . Abnormal laboratory value specify blood collect within 28 day prior randomization : 1 . Hematology Haemoglobin &lt; 9.0 g/dL &lt; 5.59 mmol/L Absolute Neutrophil Count ( ANC ) : &lt; 1000/mm3or &lt; 1.0 x 109/L Absolute Lymphocyte Count ( ALC ) : ≤ 500/mm3or ≤ 0.5 x 109/L Platelets : ≤ 90,000 ≥ 550,000/mm3or ≤ 90 x 109 ≥ 550 x 109/L 2 . Chemistry Creatinine : &gt; 1 . 1 x ULN AST : &gt; 2.6 x ULN ALT : &gt; 2.6 x ULN 3 . Urinalysis : abnormal dipstick confirm microscopy Protein 2+ Blood 2+ ( due menses ) 11 . Reported highrisk behaviour HIV infection within 3 month prior first vaccination , define : Unprotected sexual intercourse know HIVinfected person , partner know high risk HIV infection casual partner Unprotected sexual intercourse one sexual partner Engagement sex work money drug Use recreational drug ( e.g . marijuana ) and/or weekly frequent alcohol use Current past STI 12 . History evidence autoimmune disease . 13 . Positive Hepatitis B surface antigen ( HbsAg ) , positive antibody Hepatitis C virus ( HCV ) active syphilis . 14 . Receipt blood blood product within previous 6 month 15 . History severe allergic reaction substance require hospitalization emergency medical care ( e.g . StevenJohnson syndrome , bronchospasm hypotension ) 16 . Prior current participation another investigational agent trial 17 . Current antituberculosis ( TB ) prophylaxis therapy 18 . If female , currently pregnant ( positive serum urine pregnancy test ) , plan get pregnant next 9months lactate 19 . History evidence systemic disease acute chronic illness , opinion investigator , may compromise volunteer 's safety interfere evaluation safety immunogenicity vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HIV/AIDS vaccine</keyword>
	<keyword>helminth infection</keyword>
	<keyword>Impact co-infection</keyword>
</DOC>